Invitae (NYSE:NVTA) Trading 7.8% Higher
Invitae (NYSE:NVTA) Trading 7.8% Higher
Invitae Co. (NYSE:NVTA – Get Rating)'s share price traded up 7.8% on Wednesday . The company traded as high as $2.78 and last traded at $2.77. 23,439 shares changed hands during trading, a decline of 100% from the average session volume of 11,116,942 shares. The stock had previously closed at $2.57.
周三，Invitae Co.(纽约证券交易所代码：NVTA-GET Rating)股价上涨7.8%。该公司股价最高涨至2.78美元，最新报2.77美元。23,439股股票在交易中易手，较11,116,942股的平均成交量下跌100%。该股此前收盘报2.57美元。
Analyst Ratings Changes
分析师评级发生变化
A number of research analysts have weighed in on the company. Cowen increased their price target on Invitae to $2.80 in a research note on Tuesday, November 15th. SVB Leerink increased their target price on Invitae from $2.50 to $3.00 and gave the stock a "market perform" rating in a research report on Wednesday, November 9th. Credit Suisse Group started coverage on Invitae in a research report on Wednesday, August 24th. They issued an "underperform" rating on the stock. JPMorgan Chase & Co. lowered Invitae from a "neutral" rating to an "underweight" rating in a research report on Wednesday, August 10th. Finally, William Blair reaffirmed a "market perform" rating on shares of Invitae in a research report on Tuesday, November 8th. Four equities research analysts have rated the stock with a sell rating and nine have given a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $8.04.
许多研究分析师都对该公司发表了看法。考恩在11月15日星期二的一份研究报告中将Invitae的目标价上调至2.80美元。SVB Leerink在11月9日(周三)的一份研究报告中将Invitae的目标价从2.50美元上调至3.00美元，并给予该股“市场表现”评级。瑞士信贷集团在8月24日星期三的一份研究报告中开始对Invitae进行报道。他们对该股给予了“表现不佳”的评级。摩根大通公司在8月10日星期三的一份研究报告中将Invitae的评级从中性下调至减持。最后，威廉·布莱尔在11月8日星期二的一份研究报告中重申了对Invitae股票的“市场表现”评级。4名股票研究分析师对该股的评级为卖出，9名分析师对该股的评级为持有。根据MarketBeat的数据，该股的普遍评级为持有，平均目标价为8.04美元。
Invitae Price Performance
Invitae性价比
The firm has a 50 day moving average price of $2.58 and a two-hundred day moving average price of $2.93. The company has a debt-to-equity ratio of 10.03, a quick ratio of 6.18 and a current ratio of 6.44.
该公司的50日移动均线价格为2.58美元，200日移动均线价格为2.93美元。该公司的负债权益比率为10.03，速动比率为6.18，流动比率为6.44。
Institutional Trading of Invitae
Invitae的制度性交易
Several large investors have recently modified their holdings of the business. Arizona State Retirement System grew its stake in shares of Invitae by 4.6% during the first quarter. Arizona State Retirement System now owns 55,072 shares of the medical research company's stock valued at $439,000 after acquiring an additional 2,425 shares in the last quarter. Mackenzie Financial Corp grew its stake in Invitae by 25.1% in the second quarter. Mackenzie Financial Corp now owns 13,948 shares of the medical research company's stock worth $34,000 after purchasing an additional 2,795 shares in the last quarter. Private Advisor Group LLC grew its stake in Invitae by 9.7% in the first quarter. Private Advisor Group LLC now owns 32,282 shares of the medical research company's stock worth $258,000 after purchasing an additional 2,845 shares in the last quarter. SG Americas Securities LLC grew its stake in Invitae by 42.1% in the first quarter. SG Americas Securities LLC now owns 10,341 shares of the medical research company's stock worth $82,000 after purchasing an additional 3,062 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Invitae by 5.1% in the first quarter. Envestnet Asset Management Inc. now owns 63,738 shares of the medical research company's stock worth $508,000 after purchasing an additional 3,096 shares in the last quarter. 88.27% of the stock is currently owned by institutional investors and hedge funds.
几家大型投资者最近调整了对该公司的持股。亚利桑那州立退休系统第一季度在Invitae的持股增加了4.6%。亚利桑那州退休系统现在拥有55,072股这家医学研究公司的股票，价值439,000美元，在上个季度额外购买了2,425股。麦肯齐金融公司第二季度在Invitae的持股增加了25.1%。麦肯锡金融公司(Mackenzie Financial Corp)目前持有这家医疗研究公司13,948股股票，价值34,000美元，上一季度又购买了2,795股。Private Advisor Group LLC在第一季度增持了Invitae 9.7%的股份。Private Advisor Group LLC现在持有这家医疗研究公司32,282股股票，价值258,000美元，上个季度又购买了2,845股。第一季度，SG America Securities LLC在Invitae的持股增加了42.1%。SG America Securities LLC现在持有这家医疗研究公司10,341股股票，价值82,000美元，上个季度又购买了3,062股。最后，Envestnet Asset Management Inc.在第一季度增持了Invitae 5.1%的股份。Envestnet Asset Management Inc.现在持有这家医疗研究公司63,738股股票，价值508,000美元，上个季度又购买了3,096股。88.27%的股票目前由机构投资者和对冲基金持有。
About Invitae
关于Invitae
(Get Rating)
(获取评级)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
Invitae公司是一家医学遗传学公司，将遗传信息整合到主流医学中，以改善美国、加拿大和国际上人们的医疗保健。该公司提供各种临床领域的基因测试，包括遗传癌、心脏病学、神经病学、儿科、肿瘤学、代谢疾病和罕见疾病；数字健康解决方案；以及健康数据服务。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- 免费获取StockNews.com关于Invitae的研究报告(NVTA)
- 机构对ADI的支持仍然很高
- Salesforce裁员，尽管面临挑战，但收入强劲
- 微软股票：是时候备份卡车了吗？
- 60/40的投资组合组合还在《时尚》杂志上流行吗？
- 三只CBD股票将主宰一个萌芽行业
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.
接受《邀请日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Invitae和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。